A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland

Exclusion Criteria

• •1. Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period
• •2. Prior receipt of an investigational Ebola or Marburg vaccine or a chimpanzee adenovirus vectored vaccine
• •3. Receipt of any live, attenuated vaccine within 28 days prior to enrolment
• •4. Receipt of any subunit or killed vaccine within 14 days prior to enrolment (influenza vaccination is encouraged prior to participation)
• •5. Receipt of any investigational vaccine within 3 months prior to enrollment
• •6. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
• •7. Any confirmed or suspected immunosuppressed or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressive medication within the past 6 months (inhaled and topical steroids are allowed)
• •8. History of allergic reactions likely to be exacerbated by any component of the vaccine,
• •9. Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.
• •10. Any history of anaphylaxis in reaction to vaccination
• •11. Pregnancy, lactation or willingness/intention to become pregnant during the study
• •12. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
• •13. History of serious psychiatric condition
• •14. Poorly controlled asthma or thyroid disease
• •15. Seizure in the past 3 years or treatment for seizure disorder in the past 3 years
• •16. Bleeding disorder (eg. Factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venepuncture
• •17. Any other serious chronic illness requiring hospital specialist supervision
• •18. Current anti-tuberculosis prophylaxis or therapy
• •19. Suspected or known current alcohol abuse
• •20. Suspected or known injecting drug abuse in the 5 years preceding enrolment
• •21. Seropositive for hepatitis B surface antigen (HBsAg)
• •22. Seropositive for hepatitis C virus (antibodies to HCV)
• •23. Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis
• •24. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data